Tobira Therapeutics 10-Q 6 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Nov. 04, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'RGDO	'
Entity Registrant Name	'REGADO BIOSCIENCES INC	'
Entity Central Index Key	'0001311596	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	33,609,212

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$60,680	$30,688
Restricted cash	1,082	82
Prepaid expenses	1,247	2,147
Other assets	5,517	6,211
Total current assets	68,526	39,128
Property and equipment, net	316	108
Intangible assets, net	1,350	1,823
Other non-current assets	'	4,694
Total assets	70,192	45,753
Current liabilities:	'	'
Accounts payable	4,105	1,557
Accrued expenses	8,259	5,524
Warrant liability	1	19
Current portion of long-term debt	4,089	2,000
Total current liabilities	16,454	9,100
Long-term debt	'	2,452
Total liabilities	16,454	11,552
Commitments and contingencies	'	'
Stockholders' equity:	'	'
Common stock, $0.001 par value; 500,000,000 shares authorized; 33,609,212 and 21,310,614 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively	34	21
Additional paid-in-capital	232,190	179,159
Accumulated deficit	-203,318	-144,979
Total stockholders' equity	53,738	34,201
Total liabilities and stockholders' equity	70,192	45,753
Series F Convertible Preferred Stock [Member]	'	'
Stockholders' equity:	'	'
Convertible preferred stock	$24,832	'

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	33,609,212	21,310,614
Common stock, shares outstanding	33,609,212	21,310,614
Series F Convertible Preferred Stock [Member]	'	'
Convertible preferred stock, par value	$1,000	$1,000
Convertible preferred stock, shares authorized	1,000,000	1,000,000
Convertible preferred stock, shares issued	10,000	0
Convertible preferred stock, shares outstanding	10,000	0

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Statement of Comprehensive Income [Abstract]	'	'	'	'
Total revenue	'	'	'	'
Operating expenses:	'	'	'	'
Research and development	-17,709	-9,597	-49,330	-15,594
General and administrative	-3,249	-1,614	-8,635	-4,240
Total operating expenses	-20,958	-11,211	-57,965	-19,834
Loss from operations	-20,958	-11,211	-57,965	-19,834
Other (expense) income:	'	'	'	'
Interest income	34	2	84	71
Interest expense	-136	-146	-458	-545
Other income (expense)	'	-60	'	'
Total other expense	-102	-204	-374	-474
Net loss	-21,060	-11,415	-58,339	-20,308
Deemed dividend related to beneficial conversion feature of Series F convertible preferred stock	'	'	-14,840	'
Net loss attributable to stockholders	-21,060	-11,415	-73,179	-20,308
Net loss attributable to preferred stockholders	1,183	'	3,329	'
Net loss attributable to common stockholders - basic and diluted	-19,877	-11,415	-69,850	-20,308
Comprehensive loss applicable to all stockholders	($21,060)	($11,415)	($73,179)	($20,308)
Loss per share - basic and diluted	($0.59)	($1.43)	($2.35)	($7.18)
Weighted-average common shares - basic and diluted	33,609,212	8,005,142	29,664,548	2,828,757

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Cash flows used in operating activities:	'	'
Net loss	($58,339)	($20,308)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation	86	41
Amortization of patents and licenses	114	75
Impairment of patents	748	10
Impairment of clinical trial supplies	8,190	'
Impairment of prepaid expenses	465	'
Accrued final bank fee	65	33
Amortization of debt discount	72	37
Amortization of debt issuance costs	8	100
Change in fair value of warrant liability	-18	-56
Stock-based compensation	1,641	346
Loss on disposal of property and equipment	15	'
Other	'	64
Changes in operating assets and liabilities:	'	'
Prepaid expenses	435	-4,832
Other assets	-7,496	-244
Other non-current assets	4,686	-1,855
Accounts payable	2,548	221
Accrued expenses	2,735	4,242
Net cash used in operating activities	-44,045	-22,126
Cash flows used in investing activities:	'	'
Change in restricted cash	-1,000	'
Purchase of property and equipment	-309	-77
Patent and license acquisition costs	-389	-415
Proceeds received from sale of patents	'	100
Net cash used in investing activities	-1,698	-392
Cash flows from financing activities:	'	'
Proceeds from borrowings on bank loan	'	4,500
Repayment of borrowings on bank loan	-500	-4,500
Payment of bank origination fee	'	-85
Payment of debt issuance costs	'	-57
Proceeds from issuance of common stock, net of underwriting discounts and fees	76,723	43,418
Payment of offering costs	-541	-2,231
Proceeds from sale of preferred stock, net of issuance costs	'	10,163
Proceeds from issuance of common stock from exercise of options and warrants	53	'
Proceeds from exercise of warrants	'	2
Net cash provided by financing activities	75,735	51,210
Net increase in cash and cash equivalents	29,992	28,692
Cash and cash equivalents, beginning of period	30,688	14,764
Cash and cash equivalents, end of period	60,680	43,456
Supplemental disclosures of cash flow information:	'	'
Cash paid for interest	248	465
Supplemental disclosure of non-cash investing and financing activities:	'	'
Exchange of common stock for convertible preferred stock, net of issuance costs	24,832	'
Stock issued for cash held in escrow	'	5,155
Series F Convertible Preferred Stock [Member]	'	'
Supplemental disclosure of non-cash investing and financing activities:	'	'
Fair value of Series F Preferred Stock beneficial conversion feature	14,840	'
Accretion of deemed dividend on Series F Convertible Preferred Stock	($14,840)	'

Organization_and_Description_o

Organization and Description of Business	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Organization and Description of Business	'
	1. Organization and Description of Business
	Regado Biosciences, Inc. (the “Company” or “we” or “our” or “us”) is a development stage enterprise incorporated in the State of Delaware on December 19, 2001, operating primarily in Basking Ridge, New Jersey and Durham, North Carolina. We have been focused on the discovery and development of novel, first-in-class, actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications. On August 25, 2014, we announced the permanent termination of enrollment in our REGULATE-PCI phase 3 trial for our lead program, Revolixys™ Kit, formerly known as REG1. The decision was made based on a recommendation from the trial’s Data and Safety Monitoring Board, or DSMB, following their analysis of the data from the first approximately 3,250 patients enrolled in what was intended to be a 13,200-patient trial comparing the safety and efficacy of Revolixys Kit with bivalirudin. Prior to the substantial suspension of our clinical development activities, we were conducting the REGULATE-PCI trial to evaluate Revolixys™ Kit, a two-component system consisting of pegnivacogin, an anticoagulant aptamer specifically targeting coagulation Factor IXa, and its complementary oligonucleotide active control agent, anivamersen. Revolixys was being developed for use in patients with a wide variety of acute coronary syndromes, or ACS, undergoing a percutaneous coronary intervention, or PCI, a hospital-based procedure used to mechanically open or widen obstructed coronary arteries.
	In September 2014, we announced that our Board of Directors retained MTS Health Partners, L.P., or MTS, and Cowen & Company, LLC, or Cowen, to act as financial advisors in connection with our exploration of potential business alternatives. In addition, the Company announced the restructuring activities described in Note 12 to reduce costs following the termination of the REGULATE-PCI trial as part of the Company’s decision to focus resources on three principal activities following the termination of the trial: completion of the final closure of the REGULATE-PCI trial and analysis of the unblinded database from the trial, diligence activities associated with thoroughly exploring potential business alternatives, and the Company’s compliance activities associated with being a public company in good regulatory standing. Our evaluation of potential business alternatives entails numerous significant risks and uncertainties, including the risks and uncertainties set forth in Item 1A under the heading “Risk Factors” of this Quarterly Report on Form 10-Q in our Annual Report on Form 10-K. There can be no assurance that our evaluation of potential business alternatives will result in any transaction.

Basis_of_Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Basis of Presentation	'
	2. Basis of Presentation
	Principles of Consolidation
	In March 2013, we incorporated Regado Biosciences Europe Limited, a wholly owned subsidiary registered in England and Wales, in order to establish a legal presence in the European Union (the “EU”) for the purpose of conducting clinical trials in the EU. Regado Biosciences Europe Limited had no operations during the three or nine months ended September 30, 2014 and 2013.
	The accompanying consolidated financial statements include the accounts of Regado Biosciences, Inc. and its wholly owned subsidiary, Regado Biosciences Europe Limited. All intercompany balances and transactions have been eliminated in consolidation.
	Unaudited Interim Financial Data
	The accompanying interim consolidated financial statements are unaudited. These unaudited consolidated financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information under Article 210.8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles, or GAAP, for complete financial statements. These unaudited interim consolidated financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December 31, 2013 contained in the Company’s Annual Report on Form 10-K. The unaudited interim consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments necessary to state fairly our financial position as of September 30, 2014, the results of our operations for the three and nine months ended September 30, 2014 and 2013, and our cash flows for the nine months ended September 30, 2014 and 2013. The results of operations for the three and nine months ended September 30, 2014 are not necessarily indicative of the operating results for the full year or any other interim period.
	Liquidity
	Our financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and settlement of liabilities and commitments in the normal course of business. Operations since inception have consisted primarily of developing and acquiring product technologies and securing financing.
	The accompanying financial statements have been prepared assuming that we will operate as a going concern. We have had negative cash flows from operating activities of $44.0 million during the nine months ended September 30, 2014. Prior to our initial public offering (“IPO”), we were funded primarily through the issuance of preferred stock and debt. We will continue to closely monitor and analyze expenses and make adjustments as necessary to prioritize business operations. Following the restructuring described in Note 12, and assuming that a transaction involving a potential business alternative is not consummated, we believe that the net proceeds from our recent common stock offerings to new and existing investors (see Note 8) will be sufficient for us to fund our reduced operations for the foreseeable future.
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
	Clinical Trial Supplies
	Historically, we capitalized materials that were to be used in our REGULATE-PCI clinical trial that had an alternative future use in either ongoing or future clinical research or development projects. Clinical trial supplies may comprise material used to manufacture active pharmaceutical ingredients (“API”) used to develop our product candidates, in-process or completed API, in-process or completed unlabeled finished drug product and labeled finished drug product. With the termination of the REGULATE-PCI trial and suspension of development activities we have, and will continue, to expense these supplies.
	We utilize contract manufacturing organizations, or CMOs, to produce API and finished drug product for use in clinical trials. As we do not have facilities that meet the requisite regulatory requirements for storage of API or finished drug product produced, we use a third-party facility for storage. Upon release from the manufacturer, API is shipped to a third-party storage facility. For production of finished drug product, API is shipped from the storage facility to the finished drug product manufacturing site. Unlabelled finished drug product is either shipped from the manufacturer back to the third-party storage facility or directly to the third-party labeling site. Labeled finished drug product is held by the third-party labeling site until it is shipped to the clinical sites for trial use.
	As of September 30, 2014 we wrote down $8.2 million, to R&D expenses, which was the recorded value of all clinical trial supplies. As of December 31, 2013, clinical trial supplies included in other current assets were $4.6 million of which $1.6 million and $3.0 million represented API held at the third party storage facility and drug product located at depots, respectively.
	Clinical Agreements
	We enter into various clinical trial agreements with academic research organizations (“AROs”) and clinical research organizations (“CROs”) for the planning, management and execution of clinical trials. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones are met. Costs for ARO and CRO contracts are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided by vendors on their actual costs incurred; such costs are charged to research and development expense in the accompanying consolidated statements of comprehensive loss. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the research and development expense. Upfront contract signing fees are amortized over the life of the respective contract; unamortized contract signing fees are included in other current assets. Cumulative amortization costs are $1.0 million as of September 30, 2014.
	In the accompanying consolidated balance sheet as of September 30, 2014, other current assets include $3.9 million of upfront payments of which $2.8 million will be applied to final invoices as required under the respective contract, and $1.1 million will be amortized as contract signing costs in the fourth quarter of 2014, which is the revised expected completion date for the contract. By comparison, prepaid expenses on the December 31, 2013 consolidated balance sheet included $1.1 million related to clinical agreements. Other non-current assets on December 31, 2013 included $4.5 million of upfront payments of which $2.8 million will be applied to final invoices as required under the respective contract, and $1.7 million were to be amortized as contract signing costs over the remaining life of the respective contract, or approximately three years.
	In general, our ARO and CRO service agreements permit either party to terminate at will, although we would continue to be responsible for payment of all services completed (or pro-rata completed) at the time of notice of termination, plus any non-cancellable expenses that have been entered into by the ARO and CRO on the Company’s behalf. Accordingly, such expenses would be accrued at time of contract termination and any prepaid expenses and unamortized advance payments would be expensed, accordingly.
	Restricted Cash
	The Company has accrued $1.0 million for license obligations to Archemix. The funds are classified in restricted cash and are on deposit in an interest-bearing escrow account pending payment.
	Intangible Assets
	The Company’s policy is to file patent application(s) to protect technology, inventions and improvements that are considered important to the development of its business. The patent positions of technology companies, including the Company, are uncertain and involve complex legal and factual questions for which important legal principles are largely unresolved. Upon receipt of a patent grant, respective costs are amortized over the remaining life of the patent. Given the current status of the Company, any patents approved subsequent to September 30, 2014 will be expensed.
	The Company amortizes license agreements over the stated contractual life.
	Research and Development
	Research and development (“R&D”) expenses include direct and indirect R&D costs. Direct R&D consists principally of external costs, such as fees paid to investigators, license and patent amortization and related impairment, consultants central laboratories and clinical research organizations, including costs incurred in connection with our clinical trials, and related clinical trial fees and all employee-related expenses for those employees working in research and development functions, including stock-based compensation for R&D personnel. Indirect R&D costs include overhead costs related to facilities, depreciation, insurance, and small supplies that are not allocated to specific product candidates or indications. R&D costs are expensed as incurred.
	Stock-based Compensation
	In accordance with ASC Topic 718, Stock Compensation, as modified or supplemented, we measure compensation cost for share-based payment awards granted to employees and non-employee directors at fair value using the Black-Scholes option-pricing model. We recognize compensation expense on a straight-line basis over the service period for awards expected to vest. Share-based compensation cost related to share-based payment awards granted to non-employees is adjusted each reporting period for changes in the fair value of our common stock until the measurement date. The measurement date is generally considered to be the date when all services have been rendered or the date that options are fully vested.
	Series F Convertible Preferred Stock
	The Series F convertible preferred stock was deemed to have a beneficial conversion feature (a “BCF”). See Note 8 for further detail regarding the accounting for the Series F convertible preferred stock and this feature.
	Net Loss per Share
	Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of convertible preferred stock, options outstanding under our stock option plan and warrants.

Recently_Issued_Accounting_Pro

Recently Issued Accounting Pronouncements	9 Months Ended
	Sep. 30, 2014
Accounting Changes and Error Corrections [Abstract]	'
Recently Issued Accounting Pronouncements	'
	3. Recently Issued Accounting Pronouncements
	In June of 2014 the Financial Accounting Standards Board issued Accounting Standards Update ASU 2014-10, Development Stage Entities (Topic 915) “Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation” (“ASU 2014-10”). The amendments in ASU 2014-10 remove the definition of a development stage entity from the master glossary of the Accounting Standards Codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of comprehensive loss, cash flows, and changes in stockholders’ equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The amendments in ASU 2014-10 will be effective prospectively for annual reporting periods beginning after December 15, 2014, and interim periods within those annual periods, however early adoption is permitted. We have elected to early adopt the provisions of ASU 2014-10 for the current period presented. Other than the changes in presentation noted above, the adoption of ASU 2014-10 did not have significant impact on our results of operations, financial condition or cash flows.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value of Financial Instruments	'
	4. Fair Value of Financial Instruments
	The following table (in thousands) sets forth our assets and liabilities that were measured at fair value on a recurring basis at September 30, 2014 and at December 31, 2013 by level within the fair value hierarchy. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.
		As of September 30, 2014									As of December 31, 2013
	Assets and Liabilities	Quoted Prices			Significant		Significant		Balance as of		Quoted Prices		Significant		Significant		Balance at
		In Active			Other		Unobservable		September 30,		In Active		Other		Unobservable		December 31,
		Markets for			Observable		Inputs		2014		Markets for		Observable		Inputs		2013
		Identical			Inputs		(Level 3)				Identical		Inputs		(Level 3)
		Assets			(Level 2)						Assets		(Level 2)
		(Level 1)									(Level 1)
	Assets:
	Money market funds	$	59,862		$	—	$	—	$	59,862	$	30,325	$	—	$	—	$	30,325
	Total assets at fair value	$	59,862		$	—	$	—	$	59,862	$	30,325	$	—	$	—	$	30,325
	Liabilities:
	Warrant liability	$	—		$	—	$	1	$	1	$	—	$	—	$	19	$	19
	Total liabilities at fair value	$	—		$	—	$	1	$	1	$	—	$	—	$	19	$	19
	The change in the fair value measurement using significant unobservable inputs (Level 3) is summarized below (in thousands):
	Balance at December 31, 2013	$	19
	Change in fair value recorded as interest income		(69	)
	Change in fair value recorded as interest expense		51
	Balance at September 30, 2014	$	1
	The warrant liability represents our allocation of a portion of the proceeds from the May 2013 Comerica Loan (as defined in Note 6). The allocation of the proceeds from the Comerica Loan was based on the fair value of the warrant liability on the date of grant. We accounted for equity contracts not indexed to the issuer’s own stock and not meeting the definition of a derivative as an asset or liability. We utilized the Binomial pricing model to determine the fair value of the warrant liability. We record changes in the fair value of the warrant liability as interest expense or interest income, as applicable.
	We used significant assumptions in estimating the fair value of the warrant liability including the estimated volatility, risk free interest rate, estimated fair value of the preferred shares, and the estimated life of the warrant. These assumptions were used to establish an expected set of cash flows which were probability-weighted and discounted to present value to determine a fair value.

Accrued_Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2014
Payables and Accruals [Abstract]	'
Accrued Expenses	'
	5. Accrued Expenses
	The components of accrued expenses are as follows (in thousands):
		September 30,		December 31,
		2014		2013
	Accrued license milestones	$	1,000	$	1,000
	Accrued obligations under clinical contracts		3,520		1,957
	Accrued legal and professional services		144		152
	Accrued VAT expenses		780		780
	Accrued interest		21		24
	Accrued compensation and benefits		2,402		1,225
	Accrued expenses, other		392		386
	Total accrued expenses	$	8,259	$	5,524

Longterm_Debt

Long-term Debt	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Long-term Debt	'
	6. Long-term Debt
	In May 2011, we entered into a loan and security agreement with MidCap Financial SBIC, LP pursuant to which we borrowed a total of $6.0 million, at the stated rate of LIBOR, at a 2% rate floor, plus 8% spread per annum. The loan was payable in monthly installments beginning September 2013 through August 2014. Our assets (including intellectual property) were collateral for the borrowings, and we were required to pay a 3% final payment of $180,000 regardless of when the loan was paid in full.
	On May 13, 2013, we secured a venture debt loan with Comerica Bank (the “Comerica Loan”). We borrowed $4.5 million (“Tranche One”), and the proceeds of the loan were utilized to repay all amounts due to MidCap Financial SBIC, LP. The Comerica Loan bears interest at Comerica’s Prime Reference Rate (as defined in the Loan Agreement) subject to a floor of 30 day LIBOR plus 250 basis points plus 4.0%, or 7.25% as of September 30, 2014. The terms allow for an interest only period of 15 months, and the remaining principal and interest will be repaid starting September 2014 over a nine-month period (24 months in total). Maturities for 2014 and 2015 are $4.5 million and $0, respectively. Upon (i) Comerica’s receipt of evidence satisfactory to Comerica that the 1,000 patient interim analysis in the REGULATE-PCI study was successful and performed by April 30, 2014 and (ii) our completion of the IPO and receipt of net proceeds of at least $50.0 million prior to June 30, 2013, we had the option to borrow an additional $4.0 million in the second tranche, or (“Tranche Two”). Since the latter of the Tranche Two conditions was not satisfied, Tranche Two is solely at the discretion of Comerica.
	Interest expense recorded related to the Comerica Loan, including changes in fair value of warrants, was $82,000 and $138,000 for the three months ended September 30, 2014 and 2013, respectively and $245,000 and $211,000 for the nine months ended September 30, 2014 and 2013, respectively. Interest expense recorded related to the MidCap Loan was $0 and $0 for the three months ended September 30, 2014 and 2013, respectively and $0 and $325,000 for the nine months ended September 30, 2014 and 2013, respectively.
	In connection with the funding of Tranche One, we issued to Comerica a warrant to purchase 156,250 shares of the Series E Preferred Stock at a price of $0.72 per share, or the Warrant Price, subject to adjustment for stock splits, combinations, reclassifications or exchanges and certain dilutive issuances. After giving effect to our IPO and reverse stock split, the warrant was adjusted to a warrant to purchase 9,356 shares of our common stock at a price of $12.02 per share (see Note 4).
	Under the terms of the Loan Agreement, we granted Comerica a first priority security interest in substantially all of our assets other than our intellectual property. The Loan Agreement does not contain any ongoing financial covenants.
	The Loan Agreement provides that upon the occurrence of and during a period of default as defined therein, interest on the loan will accrue at a penalty rate. Upon the occurrence and during the continuance of a default, or a material adverse event, Comerica may, at its election, make all obligations under the Loan Agreement immediately due and payable, cease advancing money or extending credit, exercise its right of setoff, foreclose on our assets, dispose of collateral at a public or private sale, and exercise any other remedies available to a secured creditor at law or in equity. Management has discussed the loan agreement with Comerica, and Comerica has indicated they are not planning to exercise their call option as the Company has adequate cash on the balance sheet and is submitting required capital repayments.
	Scheduled maturities of long-term debt are as follows (in thousands):
			September 30,
			2014
	Year ending December 31:
	2014		$	4,000
	Less: unamortized discount			(31	)
	Less—current portion			(4,089	)
	Plus—fees due at closing(1)			120
	Long-term debt, net		$	—
	-1	On the date that all of the principal and interest of the Comerica Loan become due and payable, we must pay an end of term fee of $173,000 (the “Final Fee”). The Final Fee is being accreted to interest expense over the term of the Comerica Loan.
	In accounting for the Comerica Loan, the loan was separated into debt and warrant liability components. We utilized the Binomial pricing model to determine the fair value of the warrant liability component (see Note 4). The carrying amount of the debt component was determined by deducting the fair value of the warrant liability component from the par value of the Comerica Loan as a whole. The excess of the principal amount of the Comerica Loan component over its carrying amount, referred to as the debt discount, is amortized to interest expense over the term of the loan. The warrant liability component is re-measured at each reporting date and changes in the fair value of the warrant liability are recorded as interest expense or interest income, as applicable.
	In accounting for the transaction costs related to the issuance of the Comerica Loan, we allocated the total costs incurred to the debt and warrant liability components of the Comerica Loan based on their relative values. Transaction costs totaling $85,000 attributable to the debt component are amortized to interest expense over the term of the Comerica Loan using the effective interest rate method, and transaction costs attributable to the warrant liability component were immediately expensed.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	7. Commitments and Contingencies
	On July 10, 2014, the first of two purported securities class action lawsuits was commenced in the United States District Court for the District of New Jersey, naming as defendants The Company and certain of our officers and directors. The lawsuits allege violations of the Securities Act of 1933 and the Securities Exchange Act of 1934 in connection with allegedly false and misleading statements made by us related to our Phase 3 trial of Revolixys in patients undergoing certain percutaneous coronary intervention procedures. Plaintiffs allege, among other things, that we failed to disclose facts related to the potential risk of several allergic reactions following the administration of Revolixys and therefore made false or misleading statements about Revolixys’ safety. Plaintiffs seek damages and an award of reasonable costs and expenses, including attorney’s fees. On September 8, 2014, two prospective lead plaintiffs filed motions to consolidate the lawsuits, appoint a lead plaintiff, and appoint lead counsel. On September 26, 2014, the Court consolidated the lawsuits and appointed a lead plaintiff and lead counsel. We expect the lead plaintiff to file a consolidated complaint. It is possible that additional suits will be filed, or allegations received from stockholders, with respect to these same or other matters and also naming us and/or our officers and directors as defendants. These lawsuits and any other related lawsuits are subject to inherent uncertainties, and the actual defense and disposition costs will depend upon many unknown factors. The outcome of these lawsuits is necessarily uncertain. We could be forced to expend significant resources in the defense of these suits and we may not prevail. In addition, we may incur substantial legal fees and costs in connection with these lawsuits. We have a multi-layer Directors and Officers (“D&O”) insurance policy which will provide reimbursement of the defense costs. There is not a guarantee that our insurance limits will be sufficient to cover all incurred expenses. We currently are not able to estimate the possible cost to us from these matters, as these lawsuits are currently at an early stage, and we cannot be certain how long it may take to resolve these matters or the possible amount of any damages that we may be required to pay. We have not established any reserve for any potential liability relating to these lawsuits. It is possible that we could, in the future, incur judgments or enter into settlements of claims for monetary damages. A decision adverse to our interests on these actions could result in the payment of substantial damages, or possibly fines, and could have a material adverse effect on our cash flow, results of operations and financial position.
	In April 2014, we entered into a 6-year lease agreement for 18,467 square feet of administrative office space at 106 Allen Road in Basking Ridge, NJ. The total contractual obligation is $2.1 million.

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Stockholders' Equity	'
	8. Stockholders’ Equity (in thousands except share and per share amounts)
	2014 Public Offering
	In April 2014, we consummated an underwritten public offering of 10,000,000 shares of our common stock (the “April 2014 Offering”) at a price of $6.00 per share or $5.64 per share after deducting underwriting discounts and commissions. Upon the underwriters’ exercise of the over-allotment option in connection with this offering, we issued an additional 279,461 shares of common stock resulting in total net proceeds to us of approximately $57.5 million after deducting underwriting discounts of $3.7 million and offering costs of $0.5 million. In connection with the April 2014 Offering, the Company, each of its officers and directors and certain stockholders agreed with the underwriters, subject to certain exceptions, not to dispose of or hedge any of their common stock or securities convertible into or exchangeable for shares of common stock for a 90-day period after the offering, except with the prior written consent of the underwriters. This restriction has now expired.
	Other 2014 Common and Preferred Stock Transactions
	During the first quarter of 2014, we sold 4,000,000 shares of our common stock at a purchase price of $5.00 per share to certain accredited and institutional investors (the “2014 Private Placement”), raising an aggregate of $20.0 million before sales agency fees and offering costs of approximately $1.4 million. . In connection with this financing, the Company entered into a securities purchase agreement, pursuant to which it agreed to register the resale of the shares of common stock issued in the financing.
	On March 21, 2014, we entered into an exchange agreement, (“Exchange Agreement”), with Biotechnology Value Fund, LP, Biotechnology Value Fund II, LP and Investment 10, LLC (“the Exchanging Stockholders”) pursuant to which we effected an exchange (“the Exchange”) of the 2,000,000 shares of our common stock purchased by the exchanging stockholders in our 2014 Private Placement for 10,000 shares of newly designated Series F Convertible Preferred Stock (“Series F”) with a stated value of $1,000 per share, each share of which is convertible into 200 shares of our common stock (subject to adjustment in the event of stock splits, recapitalizations and other similar events affecting our common stock).
	The preferred stock was issued without registration under the Securities Act of 1933, as amended (the “Securities Act”) in reliance on the exemption from registration contained in Section 3(a)(9) of the Securities Act.
	Series F Convertible Preferred Stock Terms
	Pursuant to the terms of the Series F, the exchanging stockholders have the right to convert the Series F into 2,000,000 shares of our common stock, determined by dividing the stated value of $1,000 per share by the conversion price of $5.00 per share, subject to adjustment in the event of stock splits, recapitalizations and other similar events affecting our common stock; provided, however, that the preferred stock cannot be converted by the exchanging stockholders if, after giving effect thereto, the exchanging stockholders would beneficially own more than 9.99% of our common stock, calculated as provided in the certificate of designation establishing the preferred stock, subject to certain exceptions.
	The holders of the preferred stock will not have the right to vote on any matter except to the extent required by Delaware law.
	Series F convertible preferred shares are entitled to dividends in the same form as dividends actually paid on shares of common stock other than dividends in the form of common stock.
	Upon the execution of a fundamental transaction which effects a merger or other change of control transaction of the Company, a holder will have the right to receive, upon any subsequent conversion of a share of Series F (in lieu of conversion shares) for each issuable conversion share, the same kind and amount of securities, cash or property as it would have been entitled to receive upon the occurrence of such fundamental transaction if it had been, immediately prior to such fundamental transaction, the holder of the shares of common stock into which such holder’s shares of Series F is then convertible.
	Accounting for the Series F Convertible Preferred Stock
	Each share of the Series F is convertible into 200 shares of common stock at any time at the option of the holder, subject to adjustment, and the beneficial ownership limitation provision noted above. The Company has recorded the Series F in equity. The initial carrying value of the Series F was $24.8 million. Upon completion of the Exchange, the conversion option of the Series F was immediately exercisable; therefore, the $14.8 million discount related to the BCF was immediately accreted to Series F, resulting in an increase in the carrying value of the Series F by $14.8 million. For the nine months ended September 30, 2014, the value of the BCF of $14.8 million was included in the Company’s net loss applicable to common shareholders (see Note 11).
	As the Series F are considered participating securities, the Series F participates in the earnings or losses of the Company. Consequently, net losses were adjusted for the deemed distributions relating to the BCF and losses attributable to preferred stockholders to calculate the net loss attributable to common stockholders for the nine months period ended September 30, 2014.
	IPO
	We completed our IPO in August 2013. Inclusive of the underwriters’ exercise of the over-allotment option in connection with the IPO in September 2013, we issued 11,671,500 shares of common stock, at a price of $4.00 per share, resulting in net proceeds to us of approximately $41.1 million after deducting underwriting discounts of $3.3 million and offering costs of $2.3 million.
	Reverse Stock Split
	In May 2013, we executed an amendment to our Fifth Amended and Restated Certificate of Incorporation instituting a 1–for-16.7 reverse split of common stock and an increase in the number of shares of common stock we are authorized to issue to 500,000,000. The par value of the common and the then outstanding convertible preferred stock were not adjusted as a result of the reverse split. All issued and outstanding common stock, options and warrants, and per share amounts contained in the financial statements have been retroactively adjusted to reflect the reverse split for all periods presented.

Stock_Based_Compensation

Stock Based Compensation	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock Based Compensation	'
	9. Stock Based Compensation
	Equity Compensation Plans
	The 2013 Equity Compensation Plan (the “2013 Plan”) adopted by our Board of Directors in May 2013, became effective upon consummation of the IPO in August 2013. There are 4,408,369 common shares authorized for issuance under the 2013 Plan of which 289,741 were available as of September 30, 2014. Upon effectiveness of the 2013 Plan, stock options outstanding under the 2004 Equity Compensation Plan (the “2004 Plan”) to acquire 1,406,910 shares of our common stock were assumed under the 2013 Plan, leaving stock options to acquire 34,342 shares of our common stock outstanding under the 2004 Plan. There will be no further awards made under the 2004 Plan.
	The 2013 Plan includes an “evergreen provision” that allows for an annual increase in the number of shares of common stock available for issuance under the 2013 Plan. The annual increase will be added on the first day of each fiscal year starting January 1, 2014, inclusive, and will be equal to five percent of the total number of shares of Common Stock outstanding on December 31st of the preceding calendar year as determined by the board of directors (the “Board”). The Board may act prior to the first day of any calendar year, to provide that there shall be no increase in the share reserve for such calendar year or that the increase in the share reserve for such calendar year shall be a lesser number of shares of Common Stock than would otherwise occur. On January 1, 2014 another 1,065,530 shares became available for grant under this evergreen provision, increasing the number of shares authorized for issuance under the 2013 Plan from 3,342,839 shares to a total of 4,408,369 shares.
	Stock Options
	We use the Black-Scholes option pricing model to determine the fair value of our stock options. The determination of the fair value of stock-based payment awards on the date of grant using an option pricing model is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. These variables include our expected stock price volatility over the term of the awards, risk-free interest rate, actual employee exercise behaviors and expected dividends.
	The following table shows the weighted average assumptions used to value stock options on the date of grant, as follows:
			Nine Months Ended September 30,
			2014
			Employee			Non-Employees
	Expected stock price volatility			55.17	%		62.71	%
	Risk-free interest rate			1.33	%		0.1	%
	Expected life of option (in years)			3.2			0.6
	Estimated dividend yield			0	%		0	%
	Weighted-average grant date fair value per share		$	2.22		$	2.06
	There were no options granted during the nine months ended September 30, 2013.
	Expected stock price volatility was calculated based on the weighted-average of historical information of similar public entities, for a period consistent with the expected life of the option. We will continue to use a weighted-average approach using other similar public entities’ volatility information until our historical volatility is relevant to measure expected volatility for future option grants. The risk-free rate was based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected life assumption. The average expected life was determined based on anticipated exercise strategy and cancellation behavior for employees and non-employee directors. For the nine months ended September 30, 2014 a forfeiture rate of 1% and 0% was used for employees and nonemployee directors, respectively. We have not paid and do not anticipate paying cash dividends; therefore, the expected dividend rate was assumed to be 0%.
	The following table summarizes our aggregate Equity Compensation Plan activity:
			Number of			Weighted Average			Weighted Average		Aggregate
			Options			Exercise Price			Contractual Term		Intrinsic Value(1)
									(in years)
	Outstanding – December 31, 2013			3,272,837
	Granted			1,292,011
	Exercised			(12,161	)
	Forfeited			(69,591	)
	Expired			(3,889	)
	Outstanding – September 30, 2014			4,483,207		$	5.41			7.73	$	(19,170,641	)
	Exercisable – September 30, 2014			2,302,226		$	5.93			6.33	$	(11,046,080	)
	-1	Intrinsic value is the excess of the fair value of the underlying common shares as of September 30, 2014 over the weighted-average exercise price. A negative intrinsic value indicates the weighted-average exercise price is greater than the fair value of the underlying common shares as of September 30, 2014.
	The total intrinsic value of options exercised during the nine months ended September 30, 2014 was $29,814.
	Stock-Based Compensation Expense
	Total stock-based compensation expense recognized based on the total grant date fair value of options vested and expected to vest was approximately $1,641,000 and $346,000 for the nine months ended September 30, 2014 and 2013, respectively. Due to the valuation allowance against our net deferred tax asset, we have never recognized a tax benefit for stock-based compensation.
	All stock options issued to nonemployees (excluding non-employee directors) have been recorded at fair value. Options issued to these nonemployees in exchange for services have resulted in expenses of $0 and $24,000, during the nine months ended September 30, 2014 and 2013, respectively.
	As of September 30, 2014, approximately $3.7 million of total unrecognized compensation cost related to unvested share options is expected to be recognized over a weighted-average period of 2.8 years.

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	10. Income Taxes
	We estimate an annual effective tax rate of 0% for the year ending December 31, 2014, as the Company incurred losses for the nine months ended September 30, 2014 and are forecasting additional losses through the end of 2014, resulting in an estimated net loss for both financial statement and tax purposes for the year ending December 31, 2014
	Due to our history of losses since inception, there is not enough evidence at this time to support that we will generate future income of a sufficient amount and nature to utilize the benefits of its net deferred tax assets. Accordingly, the deferred tax assets have been reduced by a valuation allowance, since it has been determined that it is more likely than not that all of the deferred tax assets will not be realized. Therefore, no federal or state income taxes are expected and none have been recorded as of September 30, 2014. Income taxes have been accounted for using the liability method.

Net_Loss_per_Share

Net Loss per Share	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Net Loss per Share	'
	11. Net Loss per Share
	Basic net loss per share of common stock is computed by dividing the Company’s net loss attributable to its stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share of common stock is computed by giving effect to all potentially dilutive securities, including stock options, warrants and convertible preferred stock. Basic and diluted net loss per share of common stock attributable to the Company’s stockholders was the same for all periods presented on the Consolidated Statements of Comprehensive Loss, as the inclusion of all potentially dilutive securities outstanding would have been anti dilutive. As such, the numerator and the denominator used in computing both basic and diluted net loss per share are the same for each period presented.
	In March 2014, the Company issued the Series F with a BCF (See Note 8) and recorded a deemed dividend relating to the BCF of $14.8 million for 2014. The Series F participates in earnings or losses of the Company. Consequently, net losses were adjusted for the deemed distribution relating to the BCF and losses attributable to Series F stockholders to calculate the net loss attributable to common stockholders.
	The following table presents the calculation of basic and diluted net loss per share of common stock attributable to the Company’s common stockholders (in thousands, except share and per share data):
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2014			2013			2014			2013
	Net loss per share:
	Numerator:
	Net loss	$	(21,060	)	$	(11,415	)	$	(58,339	)	$	(20,308	)
	Deemed dividend related to the beneficial conversion feature of Series F convertible preferred stock		—			—			(14,840	)		—
	Net loss attributable to common stockholders		(21,060	)		(11,415	)		(73,179	)		(20,308	)
	Net loss attributable to preferred stockholders		1,183			—			3,329			—
	Net loss attributable to common stockholders — basic and diluted		(19,877	)		(11,415	)		(69,850	)		(20,308	)
	Denominator:
	Weighted average common shares outstanding, basic and diluted		33,609,212			8,005,142			29,664,548			2,828,757
	Net loss per share attributable to common stockholders, basic and diluted	$	(0.59	)	$	(1.43	)	$	(2.35	)	$	(7.18	)
	For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to our net loss position. Securities that may potentially dilute earnings per share in the future that have not been included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common equivalent shares):
		Three months ended						Nine months ended
		September 30,						September 30,
		2014			2013			2014			2013
	Convertible preferred stock		2,000,000			—			2,000,000			—
	Common stock options		4,483,207			2,818,732			4,483,207			2,818,732
	Warrants		9,356			16,332			9,356			16,332
	Total		6,492,563			2,835,064			6,492,563			2,835,064
	In August 2013, all convertible preferred stock converted into common stock in conjunction with the consummation of our IPO. During the nine months ended September 30, 2014, 6,976 warrants were exercised at a weighted average exercise price of $0.17. As of September 30, 2014 and 2013, we had 9,356 and 16,332 warrants outstanding, respectively, that were exercisable into common shares at a weighted average price of $12.02 and $0.17 per share, respectively, at the option of the warrant holder.

Restructuring

Restructuring	9 Months Ended
	Sep. 30, 2014
Restructuring and Related Activities [Abstract]	'
Restructuring	'
	12. Restructuring
	On September 24, 2014, the Company announced a workforce reduction plan to reduce costs following the termination of the REGULATE-PCI trial. Pursuant to the workforce reduction plan, the Company will eliminate approximately 60% of the Company’s workforce, or 20 employees, across all operational sites. The Company committed to the workforce reduction plan on September 17, 2014 and it is expected to be complete by the end of the Company’s 2014 fiscal year, with the majority of the reduction coming on September 30. Affected employees are being offered separation benefits, including severance payments, and temporary healthcare coverage assistance. In connection with the elimination of positions as part of the workforce reduction plan, the Company estimates incurring total charges of approximately $2 million, primarily for one-time termination benefits and facility closure expenses. . These charges will occur in the third and fourth quarters of 2014. Additionally, the Company is evaluating its facilities and the associated contractual obligations to determine the appropriate course of action. The Company currently cannot estimate these amounts, but expects to file an amended Current Report on Form 8-K within four business days of making such determination.

Subsequent_Events

Subsequent Events	9 Months Ended
	Sep. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	13. Subsequent Events
	On October 9, 2014, David J. Mazzo resigned as the Chief Executive Officer of the Company and from the Board of Directors of the Company. Dr. Mazzo’s resignation did not result from any disagreement with the Company with respect to its operations, policies or practices.
	Immediately following Dr. Mazzo’s resignation, Michael A. Metzger was appointed by the Board to succeed Dr. Mazzo, effective immediately, as Chief Executive Officer of the Company. Additionally, the Board elected Mr. Metzger to serve as a director of the Company, filling the vacancy created by Dr. Mazzo’s resignation. Mr. Metzger has served as the Company’s President and Chief Operating Officer since December 2013.

Basis_of_Presentation_Policies

Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Principles of Consolidation	'
	Principles of Consolidation
	In March 2013, we incorporated Regado Biosciences Europe Limited, a wholly owned subsidiary registered in England and Wales, in order to establish a legal presence in the European Union (the “EU”) for the purpose of conducting clinical trials in the EU. Regado Biosciences Europe Limited had no operations during the three or nine months ended September 30, 2014 and 2013.
	The accompanying consolidated financial statements include the accounts of Regado Biosciences, Inc. and its wholly owned subsidiary, Regado Biosciences Europe Limited. All intercompany balances and transactions have been eliminated in consolidation.
Unaudited Interim Financial Data	'
	Unaudited Interim Financial Data
	The accompanying interim consolidated financial statements are unaudited. These unaudited consolidated financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information under Article 210.8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles, or GAAP, for complete financial statements. These unaudited interim consolidated financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December 31, 2013 contained in the Company’s Annual Report on Form 10-K. The unaudited interim consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments necessary to state fairly our financial position as of September 30, 2014, the results of our operations for the three and nine months ended September 30, 2014 and 2013, and our cash flows for the nine months ended September 30, 2014 and 2013. The results of operations for the three and nine months ended September 30, 2014 are not necessarily indicative of the operating results for the full year or any other interim period.
Liquidity	'
	Liquidity
	Our financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and settlement of liabilities and commitments in the normal course of business. Operations since inception have consisted primarily of developing and acquiring product technologies and securing financing.
	The accompanying financial statements have been prepared assuming that we will operate as a going concern. We have had negative cash flows from operating activities of $44.0 million during the nine months ended September 30, 2014. Prior to our initial public offering (“IPO”), we were funded primarily through the issuance of preferred stock and debt. We will continue to closely monitor and analyze expenses and make adjustments as necessary to prioritize business operations. Following the restructuring described in Note 12, and assuming that a transaction involving a potential business alternative is not consummated, we believe that the net proceeds from our recent common stock offerings to new and existing investors (see Note 8) will be sufficient for us to fund our reduced operations for the foreseeable future.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Clinical Trial Supplies	'
	Clinical Trial Supplies
	Historically, we capitalized materials that were to be used in our REGULATE-PCI clinical trial that had an alternative future use in either ongoing or future clinical research or development projects. Clinical trial supplies may comprise material used to manufacture active pharmaceutical ingredients (“API”) used to develop our product candidates, in-process or completed API, in-process or completed unlabeled finished drug product and labeled finished drug product. With the termination of the REGULATE-PCI trial and suspension of development activities we have, and will continue, to expense these supplies.
	We utilize contract manufacturing organizations, or CMOs, to produce API and finished drug product for use in clinical trials. As we do not have facilities that meet the requisite regulatory requirements for storage of API or finished drug product produced, we use a third-party facility for storage. Upon release from the manufacturer, API is shipped to a third-party storage facility. For production of finished drug product, API is shipped from the storage facility to the finished drug product manufacturing site. Unlabelled finished drug product is either shipped from the manufacturer back to the third-party storage facility or directly to the third-party labeling site. Labeled finished drug product is held by the third-party labeling site until it is shipped to the clinical sites for trial use.
	As of September 30, 2014 we wrote down $8.2 million, to R&D expenses, which was the recorded value of all clinical trial supplies. As of December 31, 2013, clinical trial supplies included in other current assets were $4.6 million of which $1.6 million and $3.0 million represented API held at the third party storage facility and drug product located at depots, respectively.
Clinical Agreements	'
	Clinical Agreements
	We enter into various clinical trial agreements with academic research organizations (“AROs”) and clinical research organizations (“CROs”) for the planning, management and execution of clinical trials. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones are met. Costs for ARO and CRO contracts are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided by vendors on their actual costs incurred; such costs are charged to research and development expense in the accompanying consolidated statements of comprehensive loss. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the research and development expense. Upfront contract signing fees are amortized over the life of the respective contract; unamortized contract signing fees are included in other current assets. Cumulative amortization costs are $1.0 million as of September 30, 2014.
	In the accompanying consolidated balance sheet as of September 30, 2014, other current assets include $3.9 million of upfront payments of which $2.8 million will be applied to final invoices as required under the respective contract, and $1.1 million will be amortized as contract signing costs in the fourth quarter of 2014, which is the revised expected completion date for the contract. By comparison, prepaid expenses on the December 31, 2013 consolidated balance sheet included $1.1 million related to clinical agreements. Other non-current assets on December 31, 2013 included $4.5 million of upfront payments of which $2.8 million will be applied to final invoices as required under the respective contract, and $1.7 million were to be amortized as contract signing costs over the remaining life of the respective contract, or approximately three years.
	In general, our ARO and CRO service agreements permit either party to terminate at will, although we would continue to be responsible for payment of all services completed (or pro-rata completed) at the time of notice of termination, plus any non-cancellable expenses that have been entered into by the ARO and CRO on the Company’s behalf. Accordingly, such expenses would be accrued at time of contract termination and any prepaid expenses and unamortized advance payments would be expensed, accordingly.
Restricted Cash	'
	Restricted Cash
	The Company has accrued $1.0 million for license obligations to Archemix. The funds are classified in restricted cash and are on deposit in an interest-bearing escrow account pending payment.
Intangible Assets	'
	Intangible Assets
	The Company’s policy is to file patent application(s) to protect technology, inventions and improvements that are considered important to the development of its business. The patent positions of technology companies, including the Company, are uncertain and involve complex legal and factual questions for which important legal principles are largely unresolved. Upon receipt of a patent grant, respective costs are amortized over the remaining life of the patent. Given the current status of the Company, any patents approved subsequent to September 30, 2014 will be expensed.
	The Company amortizes license agreements over the stated contractual life.
Research and Development	'
	Research and Development
	Research and development (“R&D”) expenses include direct and indirect R&D costs. Direct R&D consists principally of external costs, such as fees paid to investigators, license and patent amortization and related impairment, consultants central laboratories and clinical research organizations, including costs incurred in connection with our clinical trials, and related clinical trial fees and all employee-related expenses for those employees working in research and development functions, including stock-based compensation for R&D personnel. Indirect R&D costs include overhead costs related to facilities, depreciation, insurance, and small supplies that are not allocated to specific product candidates or indications. R&D costs are expensed as incurred.
Stock-based Compensation	'
	Stock-based Compensation
	In accordance with ASC Topic 718, Stock Compensation, as modified or supplemented, we measure compensation cost for share-based payment awards granted to employees and non-employee directors at fair value using the Black-Scholes option-pricing model. We recognize compensation expense on a straight-line basis over the service period for awards expected to vest. Share-based compensation cost related to share-based payment awards granted to non-employees is adjusted each reporting period for changes in the fair value of our common stock until the measurement date. The measurement date is generally considered to be the date when all services have been rendered or the date that options are fully vested.
Series F Convertible Preferred Stock	'
	Series F Convertible Preferred Stock
	The Series F convertible preferred stock was deemed to have a beneficial conversion feature (a “BCF”). See Note 8 for further detail regarding the accounting for the Series F convertible preferred stock and this feature.
Net Loss per Share	'
	Net Loss per Share
	Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of convertible preferred stock, options outstanding under our stock option plan and warrants.
Recently Issued Accounting Pronouncements	'
	In June of 2014 the Financial Accounting Standards Board issued Accounting Standards Update ASU 2014-10, Development Stage Entities (Topic 915) “Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation” (“ASU 2014-10”). The amendments in ASU 2014-10 remove the definition of a development stage entity from the master glossary of the Accounting Standards Codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of comprehensive loss, cash flows, and changes in stockholders’ equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The amendments in ASU 2014-10 will be effective prospectively for annual reporting periods beginning after December 15, 2014, and interim periods within those annual periods, however early adoption is permitted. We have elected to early adopt the provisions of ASU 2014-10 for the current period presented. Other than the changes in presentation noted above, the adoption of ASU 2014-10 did not have significant impact on our results of operations, financial condition or cash flows.

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Assets and Liabilities Measured at Fair Value on a Recurring Basis	'
	Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.
		As of September 30, 2014									As of December 31, 2013
	Assets and Liabilities	Quoted Prices			Significant		Significant		Balance as of		Quoted Prices		Significant		Significant		Balance at
		In Active			Other		Unobservable		September 30,		In Active		Other		Unobservable		December 31,
		Markets for			Observable		Inputs		2014		Markets for		Observable		Inputs		2013
		Identical			Inputs		(Level 3)				Identical		Inputs		(Level 3)
		Assets			(Level 2)						Assets		(Level 2)
		(Level 1)									(Level 1)
	Assets:
	Money market funds	$	59,862		$	—	$	—	$	59,862	$	30,325	$	—	$	—	$	30,325
	Total assets at fair value	$	59,862		$	—	$	—	$	59,862	$	30,325	$	—	$	—	$	30,325
	Liabilities:
	Warrant liability	$	—		$	—	$	1	$	1	$	—	$	—	$	19	$	19
	Total liabilities at fair value	$	—		$	—	$	1	$	1	$	—	$	—	$	19	$	19
Change in Fair Value Measurement Using Significant Unobservable Inputs (Level 3)	'
	The change in the fair value measurement using significant unobservable inputs (Level 3) is summarized below (in thousands):
	Balance at December 31, 2013	$	19
	Change in fair value recorded as interest income		(69	)
	Change in fair value recorded as interest expense		51
	Balance at September 30, 2014	$	1

Accrued_Expenses_Tables

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2014
Payables and Accruals [Abstract]	'
Components of Accrued Expenses	'
	The components of accrued expenses are as follows (in thousands):
		September 30,		December 31,
		2014		2013
	Accrued license milestones	$	1,000	$	1,000
	Accrued obligations under clinical contracts		3,520		1,957
	Accrued legal and professional services		144		152
	Accrued VAT expenses		780		780
	Accrued interest		21		24
	Accrued compensation and benefits		2,402		1,225
	Accrued expenses, other		392		386
	Total accrued expenses	$	8,259	$	5,524

Longterm_Debt_Tables

Long-term Debt (Tables)	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Schedule of Long-term Debt Maturities	'
	Scheduled maturities of long-term debt are as follows (in thousands):
			September 30,
			2014
	Year ending December 31:
	2014		$	4,000
	Less: unamortized discount			(31	)
	Less—current portion			(4,089	)
	Plus—fees due at closing(1)			120
	Long-term debt, net		$	—
	-1	On the date that all of the principal and interest of the Comerica Loan become due and payable, we must pay an end of term fee of $173,000 (the “Final Fee”). The Final Fee is being accreted to interest expense over the term of the Comerica Loan.

Stock_Based_Compensation_Table

Stock Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Summary of Weighted Average Assumptions Used to Value Stock Options on Date of Grant	'
	The following table shows the weighted average assumptions used to value stock options on the date of grant, as follows:
			Nine Months Ended September 30,
			2014
			Employee			Non-Employees
	Expected stock price volatility			55.17	%		62.71	%
	Risk-free interest rate			1.33	%		0.1	%
	Expected life of option (in years)			3.2			0.6
	Estimated dividend yield			0	%		0	%
	Weighted-average grant date fair value per share		$	2.22		$	2.06
Summary of Aggregate Equity Compensation Plan Activity	'
	The following table summarizes our aggregate Equity Compensation Plan activity:
			Number of			Weighted Average			Weighted Average		Aggregate
			Options			Exercise Price			Contractual Term		Intrinsic Value(1)
									(in years)
	Outstanding – December 31, 2013			3,272,837
	Granted			1,292,011
	Exercised			(12,161	)
	Forfeited			(69,591	)
	Expired			(3,889	)
	Outstanding – September 30, 2014			4,483,207		$	5.41			7.73	$	(19,170,641	)
	Exercisable – September 30, 2014			2,302,226		$	5.93			6.33	$	(11,046,080	)
	-1	Intrinsic value is the excess of the fair value of the underlying common shares as of September 30, 2014 over the weighted-average exercise price. A negative intrinsic value indicates the weighted-average exercise price is greater than the fair value of the underlying common shares as of September 30, 2014.
	-2	The number of stock options expected to vest takes into account an estimate of expected forfeitures.

Net_Loss_per_Share_Tables

Net Loss per Share (Tables)	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Calculation of Basic and Diluted Net Loss Per Share of Common Stock Attributable to Company's Common Stockholders	'
	The following table presents the calculation of basic and diluted net loss per share of common stock attributable to the Company’s common stockholders (in thousands, except share and per share data):
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2014			2013			2014			2013
	Net loss per share:
	Numerator:
	Net loss	$	(21,060	)	$	(11,415	)	$	(58,339	)	$	(20,308	)
	Deemed dividend related to the beneficial conversion feature of Series F convertible preferred stock		—			—			(14,840	)		—
	Net loss attributable to common stockholders		(21,060	)		(11,415	)		(73,179	)		(20,308	)
	Net loss attributable to preferred stockholders		1,183			—			3,329			—
	Net loss attributable to common stockholders — basic and diluted		(19,877	)		(11,415	)		(69,850	)		(20,308	)
	Denominator:
	Weighted average common shares outstanding, basic and diluted		33,609,212			8,005,142			29,664,548			2,828,757
	Net loss per share attributable to common stockholders, basic and diluted	$	(0.59	)	$	(1.43	)	$	(2.35	)	$	(7.18	)
Schedule of Anti-Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share	'
	Securities that may potentially dilute earnings per share in the future that have not been included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common equivalent shares):
		Three months ended						Nine months ended
		September 30,						September 30,
		2014			2013			2014			2013
	Convertible preferred stock		2,000,000			—			2,000,000			—
	Common stock options		4,483,207			2,818,732			4,483,207			2,818,732
	Warrants		9,356			16,332			9,356			16,332
	Total		6,492,563			2,835,064			6,492,563			2,835,064

Organization_and_Description_o1

Organization and Description of Business - Additional Information (Detail)	0 Months Ended	9 Months Ended
	Aug. 25, 2014	Sep. 30, 2014	Aug. 25, 2014
	Patient		Patient
Collaboration Arrangement Disclosure [Abstract]	'	'	'
Date of incorporation	'	19-Dec-01	'
Number of patients enrolled	'	'	3,250
Number of subjects in Phase 3 trial	13,200	'	'

Basis_of_Presentation_Addition

Basis of Presentation - Additional Information (Detail) (USD $)	9 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Basis Of Presentation [Line Items]	'	'	'
Cash flows from operating activities	($44,045,000)	($22,126,000)	'
Clinical trial supplies written down	8,200,000	'	'
Clinical trial supplies included in other current assets	'	'	4,600,000
In-process API held at the manufacturer	'	'	1,600,000
Drug product located at depots	'	'	3,000,000
Cumulative amortization costs	1,000,000	'	'
Prepaid expenses related to clinical agreements	'	'	1,100,000
Upfront payments	3,900,000	'	4,500,000
Prepaid costs applied to final invoices	2,800,000	'	2,800,000
License obligations	8,259,000	'	5,524,000
Archemix Corporation [Member]	'	'	'
Basis Of Presentation [Line Items]	'	'	'
License obligations	1,000,000	'	'
Upfront Contract [Member]	'	'	'
Basis Of Presentation [Line Items]	'	'	'
Other non-current assets include upfront contract signing costs	'	'	1,700,000
Upfront contract signing costs amortized period	'	'	'3 years
Upfront Contract [Member] | Scenario Forecast [Member]	'	'	'
Basis Of Presentation [Line Items]	'	'	'
Other current assets include upfront contract signing costs	$1,100,000	'	'

Fair_Value_of_Financial_Instru2

Fair Value of Financial Instruments - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Assets:	'	'
Total assets at fair value	$59,862	$30,325
Liabilities:	'	'
Total liabilities at fair value	1	19
Warrant Liability [Member]	'	'
Liabilities:	'	'
Total liabilities at fair value	1	19
Money Market Funds [Member]	'	'
Assets:	'	'
Total assets at fair value	59,862	30,325
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]	'	'
Assets:	'	'
Total assets at fair value	59,862	30,325
Liabilities:	'	'
Total liabilities at fair value	'	'
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Warrant Liability [Member]	'	'
Liabilities:	'	'
Total liabilities at fair value	'	'
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Money Market Funds [Member]	'	'
Assets:	'	'
Total assets at fair value	59,862	30,325
Significant Other Observable Inputs (Level 2) [Member]	'	'
Assets:	'	'
Total assets at fair value	'	'
Liabilities:	'	'
Total liabilities at fair value	'	'
Significant Other Observable Inputs (Level 2) [Member] | Warrant Liability [Member]	'	'
Liabilities:	'	'
Total liabilities at fair value	'	'
Significant Other Observable Inputs (Level 2) [Member] | Money Market Funds [Member]	'	'
Assets:	'	'
Total assets at fair value	'	'
Significant Unobservable Inputs (Level 3) [Member]	'	'
Assets:	'	'
Total assets at fair value	'	'
Liabilities:	'	'
Total liabilities at fair value	1	19
Significant Unobservable Inputs (Level 3) [Member] | Warrant Liability [Member]	'	'
Liabilities:	'	'
Total liabilities at fair value	1	19
Significant Unobservable Inputs (Level 3) [Member] | Money Market Funds [Member]	'	'
Assets:	'	'
Total assets at fair value	'	'

Fair_Value_of_Financial_Instru3

Fair Value of Financial Instruments - Change in Fair Value Measurement Using Significant Unobservable Inputs (Level 3) (Detail) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Balance at December 31, 2013	$19
Change in fair value recorded as interest income	-69
Change in fair value recorded as interest expense	51
Balance at September 30, 2014	$1

Accrued_Expenses_Components_of

Accrued Expenses - Components of Accrued Expenses (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Payables and Accruals [Abstract]	'	'
Accrued license milestones	$1,000	$1,000
Accrued obligations under clinical contracts	3,520	1,957
Accrued legal and professional services	144	152
Accrued VAT expenses	780	780
Accrued interest	21	24
Accrued compensation and benefits	2,402	1,225
Accrued expenses, other	392	386
Total accrued expenses	$8,259	$5,524

Longterm_Debt_Additional_Infor

Long-term Debt - Additional Information (Detail) (USD $)

9 Months Ended

1 Months Ended

9 Months Ended

0 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2014

31-May-11

Sep. 30, 2014

13-May-13

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

13-May-13

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

MidCap Financial SBIC, LP [Member]

MidCap Financial SBIC, LP [Member]

Comerica Bank [Member]

Comerica Bank [Member]

Comerica Bank [Member]

Comerica Bank [Member]

Comerica Bank [Member]

Comerica Bank [Member]

Comerica Bank [Member]

Comerica Bank [Member]

Comerica Bank [Member]

MidCap Loan [Member]

MidCap Loan [Member]

MidCap Loan [Member]

MidCap Loan [Member]

Tranche Two [Member]

Series E Convertible Preferred Stock [Member]

Common Stock [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loan and security agreement, borrowed amount

'

$6,000,000

'

'

'

'

'

'

$4,500,000

'

'

'

'

'

'

'

Loan and security agreement, floor interest rate

'

2.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loan and security agreement, interest rate spread

'

8.00%

'

'

'

'

4.00%

'

'

'

'

'

'

'

'

'

Loan and security agreement, variable interest rate basis

'

'

'LIBOR

'

'

'

'

'

'

'

'

'

'

'

'

'

Loan and security agreement, interest rate description

'

'

'The stated rate of LIBOR, at a 2% rate floor, plus 8% spread per annum.

'

'

'

'

'

'

'

'

'

'

'

'

'

Final payment of loan and security agreement, percentage

'

3.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Final payment of loan and security agreement

'

180,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loan and security agreement, repayment description

'

'

'The loan was payable in monthly installments beginning September 2013 through August 2014.

'

'

'

'The terms allow for an interest only period of 15 months, and the remaining principal and interest will be repaid starting September 2014 over a nine-month period (24 months in total).

'

'

'

'

'

'

'

'

'

Loan and security agreement, repayment start date

'

'2013-09

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loan and security agreement, repayment end date

'

'2014-08

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Venture debt loan, LIBOR period

'

'

'

'

'

'

'30 days

'

'

'

'

'

'

'

'

'

Venture debt loan, basis points

'

'

'

'

2.50%

'

2.50%

'

'

'

'

'

'

'

'

'

Debt instrument term

'

'

'

'24 months

'

'

'

'

'

'

'

'

'

'

'

'

Venture debt loan, interest period

'

'

'

'15 months

'

'

'

'

'

'

'

'

'

'

'

'

Venture debt loan, interest rate

'

'

'

'

7.25%

'

7.25%

'

'

'

'

'

'

'

'

'

Due period for repayment of principal and interest

'

'

'

'9 months

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument maturity amount in 2014

'

'

'

'

'

'

4,500,000

'

'

'

'

'

'

'

'

'

Debt instrument maturity amount in 2015

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

Venture debt loan, Description

'

'

'

'

'

'

'Upon (i) Comericabs receipt of evidence satisfactory to Comerica that the 1,000 patient interim analysis in the REGULATE-PCI study is successful and performed by April 30, 2014 and (ii) our completion of the IPO and receipt of net proceeds of at least $50.0 million prior to June 30, 2013, we had the option to borrow an additional $4.0 million in the second tranche, or (bTranche Twob). Since the latter of the Tranche Two conditions was not satisfied, Tranche Two is solely at the discretion of Comerica.

'

'

'

'

'

'

'

'

'

Debt security, option to borrow additional loans

'

'

'

'

'

'

'

'

'

4,000,000

'

'

'

'

'

'

Loan and security agreement, interest expense

'

'

'

'

82,000

138,000

245,000

211,000

'

'

'

'

0

0

0

325,000

Issuance of warrants to purchase of stock

'

'

'

'

'

'

'

'

'

'

156,250

9,356

'

'

'

'

Warrant price per share

'

'

'

'

'

'

'

'

'

'

$0.72

$12.02

'

'

'

'

Transaction costs attributable to debt

$85,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Longterm_Debt_Schedule_of_Long

Long-term Debt - Schedule of Long-Term Debt Maturities (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Debt Disclosure [Abstract]	'	'
2014	$4,000	'
Less: unamortized discount	-31	'
Less - current portion	-4,089	-2,000
Plus - fees due at closing	120	'
Long-term debt, net	'	$2,452

Longterm_Debt_Schedule_of_Long1

Long-term Debt - Schedule of Long-Term Debt Maturities (Parenthetical) (Detail) (USD $)	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Debt instrument end of term fee	$173,000

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (USD $)	0 Months Ended	1 Months Ended
In Millions, unless otherwise specified	Jul. 10, 2014	Apr. 30, 2014	Sep. 08, 2014
	Plaintiff	sqft	Plaintiff
Commitments and Contingencies Disclosure [Abstract]	'	'	'
Number of purported securities class action lawsuits	2	'	'
Number of lead plaintiffs filed	'	'	2
Term of lease agreement	'	'6 years	'
Area of administrative office	'	18,467	'
Contractual liability	'	$2.10	'

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	1 Months Ended	9 Months Ended			9 Months Ended		1 Months Ended	9 Months Ended	3 Months Ended	1 Months Ended
	31-May-13	Sep. 30, 2014	Dec. 31, 2013	Mar. 21, 2014	Sep. 30, 2014	Mar. 21, 2014	Apr. 30, 2014	Sep. 30, 2014	Mar. 31, 2014	Sep. 30, 2013	Aug. 31, 2013
				Common Stock [Member]	Series F Convertible Preferred Stock [Member]	Series F Convertible Preferred Stock [Member]	April 2014 Offering [Member]	April 2014 Offering [Member]	2014 Private Placement [Member]	IPO [Member]	IPO [Member]
Subsidiary, Sale of Stock [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Common stock public offering	'	'	'	'	'	'	10,000,000	'	'	'	'
Common stock, shares issued	'	'	'	'	'	'	279,461	'	'	'	11,671,500
Common stock price per share	'	'	'	'	'	'	$6	'	$5	'	$4
Common stock price per share after deducting underwriting discounts and commissions	'	'	'	'	'	'	$5.64	'	'	'	'
Proceeds from issuance of common stock	'	$34,000	$21,000	'	'	'	$57,500,000	'	'	$41,100,000	'
Underwriting discounts	'	'	'	'	'	'	3,700,000	'	'	3,300,000	'
Offering costs	'	'	'	'	'	'	500,000	'	'	2,300,000	'
Lock in period for transfer of common stock	'	'	'	'	'	'	'	'90 days	'	'	'
Number of common stock sold	'	33,609,212	21,310,614	'	'	'	'	'	4,000,000	'	'
Proceeds from private placement	'	'	'	'	'	'	'	'	20,000,000	'	'
Offering costs	'	'	'	'	'	'	'	'	1,400,000	'	'
Equity exchange stock issued	'	'	'	2,000,000	'	'	'	'	'	'	'
Equity exchange stock received	'	'	'	'	'	10,000	'	'	'	'	'
Equity exchange par or stated value	'	$1,000	'	'	'	$1,000	'	'	'	'	'
Conversion of preferred stock into common stock	'	2,000,000	'	'	'	200	'	'	'	'	'
Conversion price of common stock	'	$5	'	'	'	'	'	'	'	'	'
Beneficial ownership for conversion of preferred stock into common stock	'	9.99%	'	'	'	'	'	'	'	'	'
Beneficial conversion feature amount	'	14,800,000	'	'	'	'	'	'	'	'	'
Carrying value of preferred stock	'	'	'	'	24,832,000	'	'	'	'	'	'
Discount related to beneficial conversion feature	'	'	'	'	14,800,000	'	'	'	'	'	'
Increase in carrying value of preferred stock	'	'	'	'	$14,800,000	'	'	'	'	'	'
Common stock, shares authorized	500,000,000	500,000,000	500,000,000	'	'	'	'	'	'	'	'
Reverse stock split ratio	16.7	'	'	'	'	'	'	'	'	'	'

Stock_Based_Compensation_Addit

Stock Based Compensation - Additional Information (Detail) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Remaining stock options outstanding to acquire common stock, assumed under the 2013 plan	4,483,207	'	3,272,837
Stock options granted	'	0	'
Expected dividend rate	0.00%	'	'
Intrinsic value of options exercised	$29,814	'	'
Stock-based compensation	1,641,000	346,000	'
Expenses related to options issued to non-employees	0	24,000	'
Total unrecognized compensation related to unvested	$3,700,000	'	'
Recognized over a weighted-average period	'2 years 9 months 18 days	'	'
2013 Plan [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Common shares authorized for future issuance	4,408,369	'	3,342,839
Common shares available for grant	289,741	'	'
Remaining stock options outstanding to acquire common stock, assumed under the 2013 plan	1,406,910	'	'
2004 Plan [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Common shares available for grant	0	'	'
Stock option to acquire common stock	34,342	'	'
Evergreen Provision [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Common shares available for grant	1,065,530	'	'
Percentage of Common Stock outstanding	5.00%	'	'
Experience Group One [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Forfeiture rate	0.00%	'	'
Experience Group Two [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Forfeiture rate	1.00%	'	'

Stock_Based_Compensation_Summa

Stock Based Compensation - Summary of Weighted Average Assumptions Used to Value Stock Options on Date of Grant (Detail) (USD $)	9 Months Ended
	Sep. 30, 2014
Employee [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Expected stock price volatility	55.17%
Risk-free interest rate	1.33%
Expected life of option (in years)	'3 years 2 months 12 days
Estimated dividend yield	0.00%
Weighted-average grant date fair value per share	$2.22
Non-Employees [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Expected stock price volatility	62.71%
Risk-free interest rate	0.10%
Expected life of option (in years)	'7 months 6 days
Estimated dividend yield	0.00%
Weighted-average grant date fair value per share	$2.06

Stock_Based_Compensation_Summa1

Stock Based Compensation - Summary of Aggregate Equity Compensation Plan Activity (Detail) (USD $)	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Number of Options, Outstanding, Beginning Balance	3,272,837
Number of Options, Granted	1,292,011
Number of Options, Exercised	-12,161
Number of Options, Forfeited	-69,591
Number of Options, Expired	-3,889
Number of Options, Outstanding, Ending Balance	4,483,207
Number of Options, Exercisable	2,302,226
Weighted Average Exercise Price, Outstanding	$5.41
Weighted Average Exercise Price, Exercisable	$5.93
Weighted Average Contractual Term, Outstanding	'7 years 8 months 23 days
Weighted Average Contractual Term, Exercisable	'6 years 3 months 29 days
Aggregate Intrinsic Value of Stock Options Outstanding	($19,170,641)
Aggregate Intrinsic Value of Stock Options Exercisable	($11,046,080)

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	0 Months Ended	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2014
		Scenario Forecast [Member]
Income Taxes [Line Items]	'	'
Income taxes effective tax rate	'	0.00%
Income taxes recorded	$0	'
Federal income taxes	0	'
State income taxes	$0	'

Net_Loss_per_Share_Additional_

Net Loss per Share - Additional Information (Detail) (USD $)	9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Dilutive Securities Included And Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Deemed dividend related to beneficial conversion feature of Series F convertible preferred stock	$14,840	'
Warrants exercised	12,161	'
Warrants outstanding	9,356	16,332
Warrants exercisable into common shares at a weighted average exercise price	$0.17	'
Outstanding warrants exercisable into common shares at a weighted average price	$5.41	'
Warrants [Member]	'	'
Dilutive Securities Included And Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Warrants exercised	6,976	'
Outstanding warrants exercisable into common shares at a weighted average price	$12.02	0.17

Net_Loss_per_Share_Calculation

Net Loss per Share - Calculation of Basic and Diluted Net Loss Per Share of Common Stock Attributable to Company's Common Stockholders (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Numerator:	'	'	'	'
Net loss	($21,060)	($11,415)	($58,339)	($20,308)
Deemed dividend related to the beneficial conversion feature of Series F convertible preferred stock	'	'	-14,840	'
Net loss attributable to common stockholders	-21,060	-11,415	-73,179	-20,308
Net loss attributable to preferred stockholders	1,183	'	3,329	'
Net loss attributable to common stockholders - basic and diluted	($19,877)	($11,415)	($69,850)	($20,308)
Denominator:	'	'	'	'
Weighted average common shares outstanding, basic and diluted	33,609,212	8,005,142	29,664,548	2,828,757
Net loss per share attributable to common stockholders, basic and diluted	($0.59)	($1.43)	($2.35)	($7.18)

Net_Loss_per_Share_Schedule_of

Net Loss per Share - Schedule of Anti-Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Detail)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Total	6,492,563	2,835,064	6,492,563	2,835,064
Convertible Preferred Stock [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Total	2,000,000	'	2,000,000	'
Common Stock Options [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Total	4,483,207	2,818,732	4,483,207	2,818,732
Warrants [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Total	9,356	16,332	9,356	16,332

Restructuring_Additional_Infor

Restructuring - Additional Information (Detail) (USD $)	0 Months Ended
In Millions, unless otherwise specified	Sep. 24, 2014
	Employees
Restructuring and Related Activities [Abstract]	'
Percentage of reduction in company's workforce eliminated	60.00%
Number of positions eliminated	20
Total restructuring charges estimated	$2